{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["3-dioxygenase 1", "epacadostat", "indoleamine 2", "inhibition mechanism", "molecular dynamic simulation", "revelation in drug design"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "32047753", "DateRevised": {"Year": "2020", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "01", "Day": "28"}], "Language": ["eng"], "ELocationID": ["164", "10.3389/fmolb.2019.00164"], "Journal": {"ISSN": "2296-889X", "JournalIssue": {"Volume": "6", "PubDate": {"Year": "2019"}}, "Title": "Frontiers in molecular biosciences", "ISOAbbreviation": "Front Mol Biosci"}, "ArticleTitle": "Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations.", "Pagination": {"StartPage": "164", "MedlinePgn": "164"}, "Abstract": {"AbstractText": ["For cancer treatment, in addition to the three standard therapies of surgery, chemotherapy, and radiotherapy, immunotherapy has become the fourth internationally-recognized alternative treatment. Indoleamine 2, 3-dioxygenase 1 (IDO1) catalyzes the conversion of tryptophan to kynurenine causing lysine depletion, which is an important target in the research and development of anticancer drugs. Epacadostat (INCB024360) is currently one of the most potent IDO1 inhibitors, nevertheless its inhibition mechanism still remains elusive. In this work, comparative molecular dynamics simulations were performed to reveal that the high inhibitory activity of INCB024360 mainly comes from two aspects: disturbing the ligand delivery tunnel and then preventing small molecules such as oxygen and water molecules from accessing the active site, as well as hindering the shuttle of substrate tryptophan with product kynurenine through the heme binding pocket. The scanning of key residues showed that L234 and R231 residues both were crucial to the catalytic activity of IDO1. With the association with INCB024360, L234 forms a stable hydrogen bond with G262, which significantly affects the spatial position of G262-A264 loop and then greatly disturbs the orderliness of ligand delivery tunnel. In addition, the cleavage of hydrogen bond between G380 and R231 increases the mobility of the GTGG conserved region, leading to the closure of the substrate tryptophan channel. This work provides new ideas for understanding action mechanism of amidoxime derivatives, improving its inhibitor activity and developing novel inhibitors of IDO1."], "CopyrightInformation": "Copyright \u00a9 2020 Liu, Zhang, Duan, Luo, Liu, Liang, Wan, Chang, Hu and Shi."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China."}], "LastName": "Liu", "ForeName": "Xinyu", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China."}], "LastName": "Zhang", "ForeName": "Yiwen", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China."}], "LastName": "Duan", "ForeName": "Huaichuan", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China."}], "LastName": "Luo", "ForeName": "Qing", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China."}], "LastName": "Liu", "ForeName": "Wei", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China."}], "LastName": "Liang", "ForeName": "Li", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Mathematics and Informatics, South China Agricultural University, Guangzhou, China."}], "LastName": "Wan", "ForeName": "Hua", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Electrical and Information Engineering, Institute of Bioinformatics and Medical Engineering, Jiangsu University of Technology, Changzhou, China."}], "LastName": "Chang", "ForeName": "Shan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China."}], "LastName": "Hu", "ForeName": "Jianping", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China."}], "LastName": "Shi", "ForeName": "Hubing", "Initials": "H"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Mol Biosci", "NlmUniqueID": "101653173", "ISSNLinking": "2296-889X"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Abril-Rodriguez G., Ribas A. (2017). SnapShot: immune checkpoint inhibitors. Cancer Cell 31, 848\u2013848.e841. 10.1016/j.ccell.2017.05.010", "ArticleIdList": ["10.1016/j.ccell.2017.05.010", "28609660"]}, {"Citation": "Antonia S. J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., et al. . (2017). Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919\u20131929. 10.1056/NEJMoa1709937", "ArticleIdList": ["10.1056/NEJMoa1709937", "28885881"]}, {"Citation": "Austin C. J., Kosim-Satyaputra P., Smith J. R., Willows R. D., Jamie J. F. (2013). Mutation of cysteine residues alters the heme-binding pocket of indoleamine 2,3-dioxygenase-1. Biochem. Biophys. Res. Commun. 436, 595\u2013600. 10.1016/j.bbrc.2013.05.119", "ArticleIdList": ["10.1016/j.bbrc.2013.05.119", "23751345"]}, {"Citation": "Bashford D., Case D. A. (2000). Generalized born models of macromolecular solvation effects. Annu. Rev. Phys. Chem. 51, 129\u2013152. 10.1146/annurev.physchem.51.1.129", "ArticleIdList": ["10.1146/annurev.physchem.51.1.129", "11031278"]}, {"Citation": "Beatty G. L., O'Dwyer P. J., Clark J., Shi J. G., Bowman K. J., Scherle P. A., et al. . (2017). First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in patients with advanced solid malignancies. Clin. Cancer Res. 23, 3269\u20133276. 10.1158/1078-0432.CCR-16-2272", "ArticleIdList": ["10.1158/1078-0432.CCR-16-2272", "PMC5496788", "28053021"]}, {"Citation": "Benkert P., Biasini M., Schwede T. (2011). Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics 27, 343\u2013350. 10.1093/bioinformatics/btq662", "ArticleIdList": ["10.1093/bioinformatics/btq662", "PMC3031035", "21134891"]}, {"Citation": "Brahmer J., Reckamp K. L., Baas P., Crino L., Eberhardt W. E., Poddubskaya E., et al. . (2015). Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135. 10.1056/NEJMoa1504627", "ArticleIdList": ["10.1056/NEJMoa1504627", "PMC4681400", "26028407"]}, {"Citation": "Brochez L., Chevolet I., Kruse V. (2017). The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur. J. Cancer 76, 167\u2013182. 10.1016/j.ejca.2017.01.011", "ArticleIdList": ["10.1016/j.ejca.2017.01.011", "28324751"]}, {"Citation": "Cady S. G., Sono M. (1991). 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291, 326\u2013333. 10.1016/0003-9861(91)90142-6", "ArticleIdList": ["10.1016/0003-9861(91)90142-6", "1952947"]}, {"Citation": "Chang M. Y., Smith C., DuHadaway J. B., Pyle J. R., Boulden J., Soler A. P., et al. . (2011). Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol. Ther. 12, 1050\u20131058. 10.4161/cbt.12.12.18142", "ArticleIdList": ["10.4161/cbt.12.12.18142", "PMC3335939", "22157149"]}, {"Citation": "Chauhan N., Basran J., Efimov I., Svistunenko D. A., Seward H. E., Moody P. C., et al. . (2008). The role of serine 167 in human indoleamine 2,3-dioxygenase: a comparison with tryptophan 2,3-dioxygenase. Biochemistry 47, 4761\u20134769. 10.1021/bi702405a", "ArticleIdList": ["10.1021/bi702405a", "18370410"]}, {"Citation": "Colombo M. P., Piconese S. (2007). Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer 7, 880\u2013887. 10.1038/nrc2250", "ArticleIdList": ["10.1038/nrc2250", "17957190"]}, {"Citation": "Curti A., Pandolfi S., Valzasina B., Aluigi M., Isidori A., Ferri E., et al. . (2007). Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 109, 2871\u20132877. 10.1182/blood-2006-07-036863", "ArticleIdList": ["10.1182/blood-2006-07-036863", "17164341"]}, {"Citation": "Dance A. (2017). Cancer immunotherapy comes of age. Science 355:1220 10.1126/science.355.6330.1220", "ArticleIdList": ["10.1126/science.355.6330.1220"]}, {"Citation": "Fallarino F., Grohmann U., You S., McGrath B. C., Cavener D. R., Vacca C., et al. . (2006a). Tryptophan catabolism generates autoimmune-preventive regulatory T cells. Transpl. Immunol. 17, 58\u201360. 10.1016/j.trim.2006.09.017", "ArticleIdList": ["10.1016/j.trim.2006.09.017", "17157218"]}, {"Citation": "Fallarino F., Grohmann U., You S., McGrath B. C., Cavener D. R., Vacca C., et al. . (2006b). The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752\u20136761. 10.4049/jimmunol.176.11.6752", "ArticleIdList": ["10.4049/jimmunol.176.11.6752", "16709834"]}, {"Citation": "Feig M., Karanicolas J., Brooks C. L., III. (2004). MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. J. Mol. Graph. Model. 22, 377\u2013395. 10.1016/j.jmgm.2003.12.005", "ArticleIdList": ["10.1016/j.jmgm.2003.12.005", "15099834"]}, {"Citation": "Fiori A., Volpi E., Zarlenga A., Bohling G. C. (2015). Gaussian or non-Gaussian logconductivity distribution at the MADE site: what is its impact on the breakthrough curve? J. Contam. Hydrol. 179, 25\u201334. 10.1016/j.jconhyd.2015.05.004", "ArticleIdList": ["10.1016/j.jconhyd.2015.05.004", "26024951"]}, {"Citation": "Garber K. (2018). A new cancer immunotherapy suffers a setback. Science 360:588. 10.1126/science.360.6389.588", "ArticleIdList": ["10.1126/science.360.6389.588", "29748264"]}, {"Citation": "Godin-Ethier J., Hanafi L. A., Piccirillo C. A., Lapointe R. (2011). Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin. Cancer Res. 17, 6985\u20136991. 10.1158/1078-0432.CCR-11-1331", "ArticleIdList": ["10.1158/1078-0432.CCR-11-1331", "22068654"]}, {"Citation": "Hamid O., Bauer T. M., Spira A. I., Olszanski A. J., Patel S. P., Wasser J. S., et al. (2017). Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase I/II results from ECHO-202/KEYNOTE-037. J. Clin. Oncol. 35:6010 10.1200/JCO.2017.35.15_suppl.6010", "ArticleIdList": ["10.1200/JCO.2017.35.15_suppl.6010"]}, {"Citation": "Hegger R., Altis A., Nguyen P. H., Stock G. (2007). How complex is the dynamics of peptide folding? Phys. Rev. Lett. 98:028102. 10.1103/PhysRevLett.98.028102", "ArticleIdList": ["10.1103/PhysRevLett.98.028102", "17358652"]}, {"Citation": "Hill M., Tanguy-Royer S., Royer P., Chauveau C., Asghar K., Tesson L., et al. . (2007). IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur. J. Immunol. 37, 3054\u20133062. 10.1002/eji.200636704", "ArticleIdList": ["10.1002/eji.200636704", "17948274"]}, {"Citation": "Hu J., Hu Z., Zhang Y., Gou X., Mu Y., Wang L., et al. . (2016). Metal binding mediated conformational change of XPA protein:a potential cytotoxic mechanism of nickel in the nucleotide excision repair. J. Mol. Model. 22:156. 10.1007/s00894-016-3017-x", "ArticleIdList": ["10.1007/s00894-016-3017-x", "PMC5327499", "27307058"]}, {"Citation": "Hu J. P., Gong X. Q., Su J. G., Chen W. Z., Wang C. X. (2008). Study on the molecular mechanism of inhibiting HIV-1 integrase by EBR28 peptide via molecular modeling approach. Biophys. Chem. 132, 69\u201380. 10.1016/j.bpc.2007.09.008", "ArticleIdList": ["10.1016/j.bpc.2007.09.008", "18037557"]}, {"Citation": "Jinushi T., Shibayama Y., Kinoshita I., Oizumi S., Jinushi M., Aota T., et al. . (2014). Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 3, 1544\u20131552. 10.1002/cam4.309", "ArticleIdList": ["10.1002/cam4.309", "PMC4298381", "25081869"]}, {"Citation": "Jorgensen W. L., Chandrasekhar J., Madura J. D., Impey R. W., Klein M. L. (1983). Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926\u2013935. 10.1063/1.445869", "ArticleIdList": ["10.1063/1.445869"]}, {"Citation": "Kabsch W., Sander C. (1983). Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577\u20132637. 10.1002/bip.360221211", "ArticleIdList": ["10.1002/bip.360221211", "6667333"]}, {"Citation": "Katz J. B., Muller A. J., Prendergast G. C. (2008). Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222, 206\u2013221. 10.1111/j.1600-065X.2008.00610.x", "ArticleIdList": ["10.1111/j.1600-065X.2008.00610.x", "18364004"]}, {"Citation": "Kim J. M., Rasmussen J. P., Rudensky A. Y. (2007). Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191\u2013197. 10.1038/ni1428", "ArticleIdList": ["10.1038/ni1428", "17136045"]}, {"Citation": "Kollman P. A., Massova I., Reyes C., Kuhn B., Huo S., Chong L., et al. . (2000). Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889\u2013897. 10.1021/ar000033j", "ArticleIdList": ["10.1021/ar000033j", "11123888"]}, {"Citation": "Komiya T., Huang C. H. (2018). Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. Front. Oncol. 8:423. 10.3389/fonc.2018.00423", "ArticleIdList": ["10.3389/fonc.2018.00423", "PMC6180183", "30338242"]}, {"Citation": "Kottalam J., Case D. A. (1990). Langevin modes of macromolecules: applications to crambin and DNA hexamers. Biopolymers 29, 1409\u20131421. 10.1002/bip.360291008", "ArticleIdList": ["10.1002/bip.360291008", "2361153"]}, {"Citation": "Kwak G., Kim D., Nam G.-H., Wang S. Y., Kim I.-S., Kim S. H., et al. . (2017). Programmed cell death protein ligand-1 silencing with polyethylenimine-dermatan sulfate complex for dual inhibition of melanoma growth. ACS Nano 11, 10135\u201310146. 10.1021/acsnano.7b04717", "ArticleIdList": ["10.1021/acsnano.7b04717", "PMC5697980", "28985469"]}, {"Citation": "Lara P., Bauer T. M., Hamid O., Smith D. C., Gajewski T., Gangadhar T. C., et al. (2017). Epacadostat plus pembrolizumab in patients with advanced RCC: preliminary phase I/II results from ECHO-202/KEYNOTE-037. J. Clin. Oncol. 35, 4515 10.1200/JCO.2017.35.15_suppl.4515", "ArticleIdList": ["10.1200/JCO.2017.35.15_suppl.4515"]}, {"Citation": "Lewis-Ballester A., Karkashon S., Batabyal D., Poulos T. L., Yeh S. R. (2018). Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1. J. Am. Chem. Soc. 140, 8518\u20138525. 10.1021/jacs.8b03691", "ArticleIdList": ["10.1021/jacs.8b03691", "PMC6434940", "29897749"]}, {"Citation": "Lewis-Ballester A., Pham K. N., Batabyal D., Karkashon S., Bonanno J. B., Poulos T. L., et al. . (2017). Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1. Nat. Commun. 8, 1693\u20131693. 10.1038/s41467-017-01725-8", "ArticleIdList": ["10.1038/s41467-017-01725-8", "PMC5700043", "29167421"]}, {"Citation": "Li M., Bolduc A. R., Hoda M. N., Gamble D. N., Dolisca S. B., Bolduc A. K., et al. . (2014). The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J. Immunother Cancer 2:21. 10.1186/2051-1426-2-21", "ArticleIdList": ["10.1186/2051-1426-2-21", "PMC4105871", "25054064"]}, {"Citation": "Lin S. Y., Yeh T. K., Song J. S., Hung M. S., Cheng M. F., Liao F. Y., et al. . (2018). 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy. Bioorg. Chem. 77, 600\u2013607. 10.1016/j.bioorg.2018.02.010", "ArticleIdList": ["10.1016/j.bioorg.2018.02.010", "29494816"]}, {"Citation": "Liu X., Shin N., Koblish H. K., Yang G., Wang Q., Wang K., et al. . (2010). Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115, 3520\u20133530. 10.1182/blood-2009-09-246124", "ArticleIdList": ["10.1182/blood-2009-09-246124", "20197554"]}, {"Citation": "Ma C. R., Liu X. X., Yu S., Zhao S., Cook J. M. (1999). Concise synthesis of optically active ring-A substituted tryptophans. Tetrahedron Lett. 40, 657\u2013660. 10.1016/S0040-4039(98)02497-6", "ArticleIdList": ["10.1016/S0040-4039(98)02497-6"]}, {"Citation": "Macchiarulo A., Nuti R., Bellocchi D., Camaioni E., Pellicciari R. (2007). Molecular docking and spatial coarse graining simulations as tools to investigate substrate recognition, enhancer binding and conformational transitions in indoleamine-2,3-dioxygenase (IDO). Biochim. Biophys. Acta 1774, 1058\u20131068. 10.1016/j.bbapap.2007.06.007", "ArticleIdList": ["10.1016/j.bbapap.2007.06.007", "17644054"]}, {"Citation": "Madeira F., Park Y. M., Lee J., Buso N., Gur T., Madhusoodanan N., et al. . (2019). The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47, W636\u2013W641. 10.1093/nar/gkz268", "ArticleIdList": ["10.1093/nar/gkz268", "PMC6602479", "30976793"]}, {"Citation": "McGuire S. (2016). $$World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7, 418\u2013419. 10.3945/an.116.012211", "ArticleIdList": ["10.3945/an.116.012211", "PMC4785485", "26980827"]}, {"Citation": "Myint A. M., Kim Y. K. (2014). Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 48, 304\u2013313. 10.1016/j.pnpbp.2013.08.008", "ArticleIdList": ["10.1016/j.pnpbp.2013.08.008", "24184687"]}, {"Citation": "Nagato T., Celis E. (2014). A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway. Oncoimmunology 3:e28440. 10.4161/onci.28440", "ArticleIdList": ["10.4161/onci.28440", "PMC4063146", "25050210"]}, {"Citation": "Nienhaus K., Nickel E., Nienhaus G. U. (2017). Substrate binding in human indoleamine 2,3-dioxygenase 1: a spectroscopic analysis. Biochim. Biophys. Acta Proteins Proteom 1865, 453\u2013463. 10.1016/j.bbapap.2017.02.008", "ArticleIdList": ["10.1016/j.bbapap.2017.02.008", "28189796"]}, {"Citation": "Pan L., Zheng Q., Chen Y., Yang R., Yang Y., Li Z., et al. . (2018). Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors. Eur. J. Med. Chem. 157, 423\u2013436. 10.1016/j.ejmech.2018.08.013", "ArticleIdList": ["10.1016/j.ejmech.2018.08.013", "30103191"]}, {"Citation": "Pardoll D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264. 10.1038/nrc3239", "ArticleIdList": ["10.1038/nrc3239", "PMC4856023", "22437870"]}, {"Citation": "Peng Y. H., Ueng S. H., Tseng C. T., Hung M. S., Song J. S., Wu J. S., et al. . (2016). Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1. J. Med. Chem. 59, 282\u2013293. 10.1021/acs.jmedchem.5b01390", "ArticleIdList": ["10.1021/acs.jmedchem.5b01390", "26642377"]}, {"Citation": "Perez R. P., Riese M. J., Lewis K. D., Saleh M. N., Daud A., Berlin J., et al. (2017). Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I/II results of ECHO-204. J. Clin. Oncol. 35, 3003 10.1200/JCO.2017.35.15_suppl.3003", "ArticleIdList": ["10.1200/JCO.2017.35.15_suppl.3003"]}, {"Citation": "Prendergast G. C. (2008). Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27, 3889\u20133900. 10.1038/onc.2008.35", "ArticleIdList": ["10.1038/onc.2008.35", "18317452"]}, {"Citation": "Reck M., Rodriguez-Abreu D., Robinson A. G., Hui R., Csoszi T., Fulop A., et al. . (2016). Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833. 10.1056/NEJMoa1606774", "ArticleIdList": ["10.1056/NEJMoa1606774", "27718847"]}, {"Citation": "Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J., et al. . (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265. 10.1016/S0140-6736(16)32517-X", "ArticleIdList": ["10.1016/S0140-6736(16)32517-X", "PMC6886121", "27979383"]}, {"Citation": "Rohrig U. F., Majjigapu S. R., Vogel P., Zoete V., Michiein O. (2015). Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) inhibitors. J. Med. Chem. 58, 9421\u20139437. 10.1021/acs.jmedchem.5b00326", "ArticleIdList": ["10.1021/acs.jmedchem.5b00326", "25970480"]}, {"Citation": "Ryckaert J.-P., Ciccotti G., Berendsen H. J. (1977). Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327\u2013341. 10.1016/0021-9991(77)90098-5", "ArticleIdList": ["10.1016/0021-9991(77)90098-5"]}, {"Citation": "Schalper K. A. (2014). PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer. Oncoimmunology 3:e29288. 10.4161/onci.29288", "ArticleIdList": ["10.4161/onci.29288", "PMC4106164", "25083339"]}, {"Citation": "Shi J. G., Chen X. J., Punwani N. G., Williams W. V., Yeleswaram S. (2016). Potential Underprediction of warfarin drug interaction from conventional interaction studies and risk mitigation: a case study with epacadostat, an IDO1 Inhibitor. J. Clin. Pharmacol. 56, 1344\u20131354. 10.1002/jcph.737", "ArticleIdList": ["10.1002/jcph.737", "26990117"]}, {"Citation": "Simonson T. (2001). Macromolecular electrostatics: continuum models and their growing pains. Curr. Opin. Struct. Biol. 11, 243\u2013252. 10.1016/S0959-440X(00)00197-4", "ArticleIdList": ["10.1016/S0959-440X(00)00197-4", "11297935"]}, {"Citation": "Smart O. S., Neduvelil J. G., Wang X., Wallace B. A., Sansom M. S. (1996). HOLE: a program for the analysis of the pore dimensions of ion channel structural models. J. Mol. Graph. 14, 354\u2013376. 10.1016/S0263-7855(97)00009-X", "ArticleIdList": ["10.1016/S0263-7855(97)00009-X", "9195488"]}, {"Citation": "Smith D. C., Gajewski T., Mid O. H., Wasser J. S., Olszanski A. J., Patel S. P., et al. (2017). Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: preliminary phase I/II results of ECHO-202/KEYNOTE-037. J. Clin. Oncol. 35, 4503 10.1200/JCO.2017.35.15_suppl.4503", "ArticleIdList": ["10.1200/JCO.2017.35.15_suppl.4503"]}, {"Citation": "Spranger S., Koblish H. K., Horton B., Scherle P. A., Newton R., Gajewski T. F. (2014). Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother Cancer 2:3. 10.1186/2051-1426-2-3", "ArticleIdList": ["10.1186/2051-1426-2-3", "PMC4019906", "24829760"]}, {"Citation": "Sugimoto H., Oda S., Otsuki T., Hino T., Yoshida T., Shiro Y. (2006). Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc. Natl. Acad. Sci. U.S.A. 103, 2611\u20132616. 10.1073/pnas.0508996103", "ArticleIdList": ["10.1073/pnas.0508996103", "PMC1413787", "16477023"]}, {"Citation": "Sun X., Yan X., Zhuo W., Gu J., Zuo K., Liu W., et al. . (2018). PD-L1 nanobody competitively inhibits the formation of the PD-1/PD-L1 complex: comparative molecular dynamics simulations. Int. J. Mol. Sci. 19:E1984. 10.3390/ijms19071984", "ArticleIdList": ["10.3390/ijms19071984", "PMC6073277", "29986511"]}, {"Citation": "Tang J., Shalabi A., Hubbard-Lucey V. M. (2018). Comprehensive analysis of the clinical immuno-oncology landscape. Ann. Oncol. 29, 84\u201391. 10.1093/annonc/mdx755", "ArticleIdList": ["10.1093/annonc/mdx755", "29228097"]}, {"Citation": "Thorson J. S., Chapman E., Schultz P. G. (1995). Analysis of hydrogen bonding strengths in proteins using unnatural amino acids. J. Am. Chem. Soc. 117, 9361\u20139362. 10.1021/ja00141a032", "ArticleIdList": ["10.1021/ja00141a032"]}, {"Citation": "Tojo S., Kohno T., Tanaka T., Kamioka S., Ota Y., Ishii T., et al. . (2014). Crystal structures and structure-activity relationships of imidazothiazole derivatives as IDO1 inhibitors. ACS Med. Chem. Lett. 5, 1119\u20131123. 10.1021/ml500247w", "ArticleIdList": ["10.1021/ml500247w", "PMC4190630", "25313323"]}, {"Citation": "Tomek P., Palmer B. D., Flanagan J. U., Sun C., Raven E. L., Ching L. M. (2017). Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): probing the active site-inhibitor interactions. Eur. J. Med. Chem. 126, 983\u2013996. 10.1016/j.ejmech.2016.12.029", "ArticleIdList": ["10.1016/j.ejmech.2016.12.029", "28011425"]}, {"Citation": "Torre L. A., Bray F., Siegel R. L., Ferlay J., Lortet-Tieulent J., Jemal A. (2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87\u2013108. 10.3322/caac.21262", "ArticleIdList": ["10.3322/caac.21262", "25651787"]}, {"Citation": "Ul Haq F., Abro A., Raza S., Liedl K. R., Azam S. S. (2017). Molecular dynamics simulation studies of novel \u03b2-lactamase inhibitor. J. Mol. Graph. Model. 74, 143\u2013152. 10.1016/j.jmgm.2017.03.002", "ArticleIdList": ["10.1016/j.jmgm.2017.03.002", "28432959"]}, {"Citation": "van der Goot A. T., Zhu W., V\u00e1zquez-Manrique R. P., Seinstra R. I., Dettmer K., Michels H., et al. . (2012). Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc. Natl. Acad. Sci. U.S.A. 109, 14912\u201314917. 10.1073/pnas.1203083109", "ArticleIdList": ["10.1073/pnas.1203083109", "PMC3443121", "22927396"]}, {"Citation": "Wang J., Cieplak P., Kollman P. A. (2000). How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J.Comput. Chem. 21, 1049\u20131074. 10.1002/1096-987X(200009)21:12&lt;1049::AID-JCC3&gt;3.0.CO;2-F", "ArticleIdList": ["10.1002/1096-987X(200009)21:12&lt;1049::AID-JCC3&gt;3.0.CO;2-F"]}, {"Citation": "Wang W., Donini O., Reyes C. M., Kollman P. A. (2001). Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annu. Rev. Biophys. Biomol. Struct. 30, 211\u2013243. 10.1146/annurev.biophys.30.1.211", "ArticleIdList": ["10.1146/annurev.biophys.30.1.211", "11340059"]}, {"Citation": "Xie Q., Wang L., Zhu B., Wang Y., Gu J., Chen Z. (2008). The expression and significance of indoleamine\u22122,3-dioxygenase in non-small cell lung cancer cell. Zhongguo Fei Ai Za Zhi 11, 115\u2013119. 10.3779/j.issn.1009-3419.2008.01.025", "ArticleIdList": ["10.3779/j.issn.1009-3419.2008.01.025", "20727279"]}, {"Citation": "Xie T., Wu Z., Gu J., Guo R., Yan X., Duan H., et al. . (2019). The global motion affecting electron transfer in Plasmodium falciparum type II NADH dehydrogenases: a novel non-competitive mechanism for quinoline ketone derivative inhibitors. Phys. Chem. Chem. Phys. 21, 18105\u201318118. 10.1039/C9CP02645B", "ArticleIdList": ["10.1039/C9CP02645B", "31396604"]}, {"Citation": "Yamazaki F., Kuroiwa T., Takikawa O., Kido R. (1985). Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem. J. 230, 635\u2013638. 10.1042/bj2300635", "ArticleIdList": ["10.1042/bj2300635", "PMC1152665", "3877502"]}, {"Citation": "Yan D. J., Lin Y. W., Tan X. S. (2017). Heme-containing enzymes and inhibitors for tryptophan metabolism. Metallomics 9, 1230\u20131240. 10.1039/C7MT00105C", "ArticleIdList": ["10.1039/C7MT00105C", "28650043"]}, {"Citation": "Yang S. S., Li X. S., Hu F. F., Li Y. L., Yang Y. Y., Yan J. K., et al. . (2013). Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice. J. Med. Chem. 56, 8321\u20138331. 10.1021/jm401195n", "ArticleIdList": ["10.1021/jm401195n", "24099220"]}, {"Citation": "Yue E. W., Douty B., Wayland B., Bower M., Liu X. D., Leffet L., et al. . (2009). Discovery of potent competitive inhibitors of indoleamine 2,3-Dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J. Med. Chem. 52, 7364\u20137367. 10.1021/jm900518f", "ArticleIdList": ["10.1021/jm900518f", "19507862"]}, {"Citation": "Yue E. W., Sparks R., Polam P., Modi D., Douty B., Wayland B., et al. . (2017). INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology. ACS Med. Chem. Lett. 8, 486\u2013491. 10.1021/acsmedchemlett.6b00391", "ArticleIdList": ["10.1021/acsmedchemlett.6b00391", "PMC5430407", "28523098"]}, {"Citation": "Zamanakou M., Germenis A. E., Karanikas V. (2007). Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol. Lett. 111, 69\u201375. 10.1016/j.imlet.2007.06.001", "ArticleIdList": ["10.1016/j.imlet.2007.06.001", "17644189"]}, {"Citation": "Zeeberg Iversen T., Andersen M., Svane I. (2014). The targeting of IDO-mediated immune escape in cancer. Basic Clin. Pharmacol. Toxicol. 116, 19\u201324. 10.1111/bcpt.12320", "ArticleIdList": ["10.1111/bcpt.12320", "25207460"]}, {"Citation": "Zhai L., Spranger S., Binder D. C., Gritsina G., Lauing K. L., Giles F. J., et al. . (2015). Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin. Cancer Res. 21, 5427\u20135433. 10.1158/1078-0432.CCR-15-0420", "ArticleIdList": ["10.1158/1078-0432.CCR-15-0420", "PMC4681601", "26519060"]}, {"Citation": "Zheng X., Koropatnick J., Li M., Zhang X., Ling F., Ren X., et al. . (2006). Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J. Immunol. 177, 5639\u20135646. 10.4049/jimmunol.177.8.5639", "ArticleIdList": ["10.4049/jimmunol.177.8.5639", "17015752"]}]}], "History": [{"Year": "2019", "Month": "12", "Day": "16"}, {"Year": "2019", "Month": "12", "Day": "31"}, {"Year": "2020", "Month": "2", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "2", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "2", "Day": "13", "Hour": "6", "Minute": "1"}, {"Year": "2019", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["32047753", "PMC6997135", "10.3389/fmolb.2019.00164"]}}]}